| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 5, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 5, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2025 | $2.00 → $1.00 | Buy → Hold | TD Cowen |
| 5/13/2022 | $8.75 | Neutral → Buy | Alliance Global Partners |
| 1/26/2022 | $28.00 → $25.00 | Buy | Aegis Capital |
| 8/19/2021 | $35.00 → $28.00 | Buy | Aegis Capital |
TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously
Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously
4 - DarioHealth Corp. (0001533998) (Issuer)
3 - DarioHealth Corp. (0001533998) (Issuer)
3 - DarioHealth Corp. (0001533998) (Issuer)
EFFECT - DarioHealth Corp. (0001533998) (Filer)
SD - DarioHealth Corp. (0001533998) (Filer)
DEF 14A - DarioHealth Corp. (0001533998) (Filer)
Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi
SC 13G - DarioHealth Corp. (0001533998) (Subject)
SC 13G - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in value-based sleep health solutions, to bring the comprehensive care program to payers nationwide. The collaboration leverages the strengths of both companies to deliver a tiered, data-driven solution for improving member health outcomes, reducing healthcare costs, and enh
Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and
First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially.Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimizationGAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 millionNon-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5
First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially.Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimizationGAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 millionNon-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023.Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.Completed $25.6 million equity financing, resulting in a $34.5 million proforma cash balance as of year-end; proforma balance expected to fund operations through operational cash flow breakeven run rate by the end of 2025 with a larger cushion.Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of 35% to $11.7 million on a GAAP bas